current page

Newsroom 2017

March 6, 2017

Terumo and Toxikon Europe NV announce a strategic partnership
by joining the expertise of both companies to service the pharmaceutical industry

Leuven, Belgium – March 6, 2017 – Terumo Corporation and Toxikon Europe NV today announced their strategic partnership by joining the expertise of both companies to service the pharmaceutical industry. Through this partnership, both companies substantially leverage their comprehensive knowledge and broad expertise in the developing, manufacturing and testing of polymer container/closure systems for parenteral applications.

The partnership creates and offers a range of outstanding technical and scientific services, which enable Terumo to support their pharmaceutical and biopharmaceutical customers, and therefore facilitate a faster qualification and acceptance process for Terumo’s PLAJEX™ (Polymer-based prefillable syringe systems). The Toxikon Europe support relates to the extractables and leachables testing, toxicological assessments, impurity identifications and biocompatibility testing of PLAJEX™ and the associated components.

"We are very excited about this strategic partnership established with a top Contract Research Organization (CRO) who is recognised within this industry for their profound knowledge and expertise in extractable and leachable testing for pharmaceuticals and primary containers for medicinal products. Both Terumo and Toxikon take pride in providing high quality products and services that assist the pharma industry in insuring the safety and efficacy of the drug and safeguarding that patients benefit from these lifesaving medications. There is an increasing number of regulatory requirements and guidance on pharmaceutical packaging materials to emphasize the importance of extractable and leachable studies; "Tested by Toxikon" is regarded by us as a mark of quality for the thorough assessment of PLAJEX™", said Tetsuya Kumei, Executive Officer and Division President, Alliance Division, General Hospital Company, Terumo Corporation.

"It is extremely satisfying to see the long lasting professional relationship with Terumo result in this formal partnership. I consider this collaboration as a powerful opportunity to create a seamless and integrated service to support Terumo in their undertakings to further grow and expand their market share in the rapidly growing polymer prefilled syringe market. I am absolutely convinced that Toxikon Europe – with our cutting-edge technologies and state-of-the-art instrumentation – can play a vital role in a superior and swift qualification and acceptance process for the PLAJEX™ for use by the pharmaceutical and biotech industry," said Jos Bollen, Managing Director, Toxikon Europe NV.

About Terumo

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over US$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company has been manufacturing disposable needles and syringes for more than 50 years. Utilizing these experiences, Terumo started supplying polymer-based prefilled syringe (PFS) since 1999. Terumo’s PLAJEX™ (Polymer-based prefillable syringe systems), combine more than 18 years of experience with polymer pre-filled syringes. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

Terumo Corporation - 2-44-1 Hatagaya, Shibuya-ku, Tokyo, Japan

http://www.terumo.com

Terumo Europe N.V. - Researchpark Haasrode 1520, Interleuvenlaan 40, B-3001 Leuven, Belgium

http:/www.terumo-europe.com/en-EMEA

About Toxikon Europe NV

Toxikon Europe is an independent, privately owned Contract Research Organisation, specialized in providing premium Extractable & Leachable Services to the Pharmaceutical Industry. Based in Belgium, Toxikon Europe supports Pharma Companies - across the Globe - in developing worldwide compliant (FDA, EMA) Testing Strategies to qualify Container/Closure Applications and Pharmaceutical Production Equipment from an Extractable & Leachable Perspective. In addition, the Toxikon group also provides Biocompatibility Testing Services (In-Vivo and In-Vitro testing) to both the Medical Device and the Pharmaceutical Industries.
Toxikon is ISO 17025 Accredited, GLP-Certified and GMP Accredited. Toxikon is also FDA registered.

Toxikon Europe NV - Romeinsestraat 12 - B-3001 Leuven, Belgium

http://www.toxikon.be

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.

 

Return to page top